Founded in 1929, the not-for-profit organization is a leading researcher of human diseases, their causes, and their potential cures. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its own research in areas such as cancer, immunology, and metabolic disease, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe. Additionally, The Jackson Laboratory offers educational programs -- including internships, workshops, and predoctoral programs -- for both current and future scientists.

Biosite Incorporated company's diagnostic products include its Triage Drugs of Abuse Panel and Triage TOX Drug Screen which are used in hospital settings to test for commonly abused drugs. Its other diagnostic products include tests to detect intestinal parasites, diagnose congestive heart failure, and measure the biomarkers associated with stroke. The Biosite Discovery program is a collaborative research effort to identify protein markers for a variety of ailments. Medical diagnostics firm Inverness Medical Innovations acquired Biosite in 2007.

YM Biosciences was founded in 1994 and is headquartered in Mississauga, Canada. YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain. In addition, its other product candidates include TGFa and HER-1, the anti-cancer vaccines.

BioSpecifics Technologies Corp. company was founded in 1957 and is headquartered in Lynbrook, New York. BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytren's disease, peyronie's disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronie's disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite.

GlaxoSmithKline plc company was founded in 1935 and is based in Brentford, the United Kingdom. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company offers prescription medicines to treat a range of conditions, such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips and Tums. Its oral healthcare products primarily comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; and Polident, PoliGrip, and Corega, which are denture care cleansers and adhesives. Further, the company provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in Europe, North America, Central and South America, the Caribbean, Asia, Australia, the Middle East, Africa, and the Southeast Asia.

Interleukin Genetics, Inc. was founded in 1986 and is headquartered in Waltham, Massachusetts. Interleukin Genetics, Inc., together with its subsidiaries, focuses on developing, acquiring, and commercializing personalized health products that help individuals improve and maintain their health through preventive measures in the United States and internationally. It conducts, researches, develops, markets, and sells genetic test panels primarily in inflammatory and metabolic areas to provide insight into health, wellness, and disease. The company markets and distributes genetic tests under the GENSONA brand, through a strategic partnership with Alticor; and PST tests through sales and marketing partners to dentists and periodontists. It offers genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. The company has research collaborations with the University of Sheffield, Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, University of North Carolina, and Yonsei University.

Soft Gel Technologies, Inc. company makes hermetically sealed gelatin encapsulations of dietary supplements -- vitamins, minerals, fatty acids, and herbal extracts. The company manufactures more than 150 products, both private label and branded, to promote digestive health, immune system support, urinary tract wellness, and weight loss. Its brands include Carnisol, Femalgen, GlucoFit, and LyCoQ. Soft Gel Technologies also provides contract research and development, formulation, manufacturing, and sales and marketing services for other nutritional products companies. Soft Gel company is owned by Japanese chemicals firm Kenko.

Taisho Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company. Taisho Company, along with its subsidiaries and associated companies, operates in two business segment. The Self Medication segment is engaged in the research, development, manufacture and sale of self-medication pharmaceuticals, quasi drugs and food products. This segment is also involved in the provision of insurance services, logistics services, printing services, as well as real estate leasing, management and operation services. The Prescribed Medication segment is engaged in the development, manufacture and sale of prescribed pharmaceuticals. Taisho Company has 23 subsidiaries and three associated companies. The Company acquired 97.97% stake in PT Bristol-Myers Squibb Indonesia Tbk. on October 31, 2009.

Ipsen develops pharmaceutical products that target oncology, endocrinology, and neuromuscular disorders. The group additionally markets products to treat gastroenterology, cardiovascular, and cognitive disorders. Ipsen operates research-and-development (R&D) centers in Paris, Boston, Barcelona, and London, which have churned out more than 20 products to the global therapeutic market. Its R&D efforts focus on peptide engineering, protein engineering, medicinal chemistry, and advanced drug delivery. The company markets its products directly as well as through third parties, and has formed strategic development alliances with the likes of Medicis and Applied Biosystems (now part of Life Technologies Corporation).

Exelixis, Inc. company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.